These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 12853879)

  • 1. Heterogeneity of chemosensitivity of esophageal and gastric carcinoma.
    Mercer SJ; Somers SS; Knight LA; Whitehouse PA; Sharma S; Di Nicolantonio F; Glaysher S; Toh S; Cree IA;
    Anticancer Drugs; 2003 Jul; 14(6):397-403. PubMed ID: 12853879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterogeneity of chemosensitivity of colorectal adenocarcinoma determined by a modified ex vivo ATP-tumor chemosensitivity assay (ATP-TCA).
    Whitehouse PA; Knight LA; Di Nicolantonio F; Mercer SJ; Sharma S; Cree IA;
    Anticancer Drugs; 2003 Jun; 14(5):369-75. PubMed ID: 12782944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterogeneity of chemosensitivity of metastatic cutaneous melanoma.
    Cree IA; Neale MH; Myatt NE; de Takats PG; Hall P; Grant J; Kurbacher CM; Reinhold U; Neuber K; MacKie RM; Chana J; Weaver PC; Khoury GG; Sartori C; Andreotti PE
    Anticancer Drugs; 1999 Jun; 10(5):437-44. PubMed ID: 10477162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterogeneity of chemosensitivity in esophageal cancer using ATP-tumor chemosensitivity assay.
    Ling ZQ; Qi CJ; Lu XX; Qian LJ; Gu LH; Zheng ZG; Zhao Q; Wang S; Fang XH; Yang ZX; Yin J; Mao WM
    Acta Pharmacol Sin; 2012 Mar; 33(3):401-6. PubMed ID: 22286916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Correlation of chemosensitivity measured by histoculture drug response assay to expression of multidrug resistance genes and proteins in gastric cancer].
    Yuan SQ; Zhou ZW; Liang YJ; Fu LW; Chen G; Keshari RP; Zhang LY
    Ai Zheng; 2009 Apr; 28(4):337-43. PubMed ID: 19622290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro chemosensitivity in breast cancer using ATP-tumor chemosensitivity assay.
    Qi CJ; Ning YL; Zhu YL; Min HY; Ye H; Qian KQ
    Arch Pharm Res; 2009 Dec; 32(12):1737-42. PubMed ID: 20162402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical benefit of chemosensitivity test for patients with regional lymph node-positive esophageal squamous cell carcinoma.
    Nakamori M; Iwahashi M; Nakamura M; Yamaue H
    J Surg Oncol; 2003 Sep; 84(1):10-6. PubMed ID: 12949985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A successful resected case of advanced esophageal cancer with early gastric cancer responding to neoadjuvant chemotherapy of docetaxel, CDDP and 5-FU].
    Matsutani T; Yoshida H; Sasajima K; Maruyama H; Yokoyama T; Matsushita A; Hirakata A; Takao Y; Umakoshi M; Hayakawa T; Katayama H; Hosone M; Uchida E
    Gan To Kagaku Ryoho; 2012 Apr; 39(4):645-8. PubMed ID: 22504694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Relationship between the expression of P-glycoprotein, glutathione S-transferase-pi and thymidylate synthase proteins and adenosine triphosphate tumor chemosensitivity assay in cervical cancer].
    Gao GL; Wan HY; Zou XS; Chen WX; Chen YQ; Huang XZ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Mar; 42(3):201-5. PubMed ID: 17537309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I and II trial of epirubicin, cisplatin, 24-hour infusion 5 fluorouracil and sodium folinate in patients with advanced esophagogastric carcinomas.
    Karapetis CS; Cheong KA; Yip D; Strickland AH; Steer C; Marx G; Yip S; Chrystal K; Harper PG
    Asia Pac J Clin Oncol; 2010 Dec; 6(4):298-305. PubMed ID: 21114780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of first-line systemic chemotherapy with epirubicin, cisplatin plus 5-fluorouracil and docetaxel, cisplatin plus 5-fluorouracil regimens in locally advanced inoperable or metastatic gastric or gastroesophageal junction adenocarcinoma: A prospective phase II study from South India.
    Babu KG; Chaudhuri T; Lakshmaiah KC; Dasappa L; Jacob LA; Babu M; Rudresha AH; Lokesh KN; Rajeev LK
    Indian J Cancer; 2017; 54(1):47-51. PubMed ID: 29199662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase IIa study of rhLTα-Da in combination with cisplatin and fluorouracil for patients with metastatic esophageal squamous cell carcinoma or gastric adenocarcinoma.
    Wang FH; Wang Y; Chen ZD; Chen JH; Qin FZ; Jiang WQ; Li YH
    Med Oncol; 2016 Nov; 33(11):125. PubMed ID: 27743200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant chemotherapy for gastro-oesophageal cancer with epirubicin, cisplatin and fluorouracil: a single-centre experience.
    Strickland AH; Karapetis CS; Yip D; Harper PG
    Clin Oncol (R Coll Radiol); 2001; 13(1):66. PubMed ID: 11292143
    [No Abstract]   [Full Text] [Related]  

  • 14. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer.
    Ross P; Nicolson M; Cunningham D; Valle J; Seymour M; Harper P; Price T; Anderson H; Iveson T; Hickish T; Lofts F; Norman A
    J Clin Oncol; 2002 Apr; 20(8):1996-2004. PubMed ID: 11956258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.
    Al-Batran SE; Hofheinz RD; Pauligk C; Kopp HG; Haag GM; Luley KB; Meiler J; Homann N; Lorenzen S; Schmalenberg H; Probst S; Koenigsmann M; Egger M; Prasnikar N; Caca K; Trojan J; Martens UM; Block A; Fischbach W; Mahlberg R; Clemens M; Illerhaus G; Zirlik K; Behringer DM; Schmiegel W; Pohl M; Heike M; Ronellenfitsch U; Schuler M; Bechstein WO; Königsrainer A; Gaiser T; Schirmacher P; Hozaeel W; Reichart A; Goetze TO; Sievert M; Jäger E; Mönig S; Tannapfel A
    Lancet Oncol; 2016 Dec; 17(12):1697-1708. PubMed ID: 27776843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Presence of serum p53 antibodies is associated with decreased in vitro chemosensitivity in patients with esophageal cancer.
    Shimada H; Okazumi S; Takeda A; Nabeya Y; Matsubara H; Funami Y; Hayashi H; Gunji Y; Suzuki T; Ochiai T
    Surg Today; 2001; 31(7):591-6. PubMed ID: 11495153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High Impact of Histopathological Remission for Prognosis after Perioperative Chemotherapy with ECF and ECF-Like Regimens for Gastric and Gastroesophageal Adenocarcinoma.
    Bichev D; Treese C; von Winterfeld M; Breithaupt K; Dogan Y; Schmidt SC; Daum S; Thuss-Patience PC
    Oncology; 2015; 89(2):95-102. PubMed ID: 25823985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ex vivo chemosensitivity of head and neck carcinoma to cytostatic drug combinations.
    Dollner R; Granzow C; Neudert M; Dietz A
    Anticancer Res; 2006; 26(2B):1651-5. PubMed ID: 16619587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of the clinical response to chemotherapy in breast cancer with ex vivo chemosensitivity.
    Cree IA; Kurbacher CM; Untch M; Sutherland LA; Hunter EM; Subedi AM; James EA; Dewar JA; Preece PE; Andreotti PE; Bruckner HW
    Anticancer Drugs; 1996 Aug; 7(6):630-5. PubMed ID: 8913430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus.
    Ilson DH; Ajani J; Bhalla K; Forastiere A; Huang Y; Patel P; Martin L; Donegan J; Pazdur R; Reed C; Kelsen DP
    J Clin Oncol; 1998 May; 16(5):1826-34. PubMed ID: 9586897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.